- Home
- HPK vs NEO Comparison
HPK vs NEO Comparison
Compare HPK & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPK
- NEO
- Stock Information
- Founded
- HPK 2019
- NEO 2001
- Country
- HPK United States
- NEO United States
- Employees
- HPK N/A
- NEO N/A
- Industry
- HPK Oil & Gas Production
- NEO Precision Instruments
- Sector
- HPK Energy
- NEO Health Care
- Exchange
- HPK Nasdaq
- NEO Nasdaq
- Market Cap
- HPK 1.1B
- NEO 1.1B
- IPO Year
- HPK N/A
- NEO 1999
- Fundamental
- Price
- HPK $7.16
- NEO $9.11
- Analyst Decision
- HPK Sell
- NEO Buy
- Analyst Count
- HPK 2
- NEO 10
- Target Price
- HPK $11.50
- NEO $12.56
- AVG Volume (30 Days)
- HPK 433.8K
- NEO 2.9M
- Earning Date
- HPK 11-03-2025
- NEO 10-28-2025
- Dividend Yield
- HPK 2.23%
- NEO N/A
- EPS Growth
- HPK N/A
- NEO N/A
- EPS
- HPK 0.86
- NEO N/A
- Revenue
- HPK $964,232,000.00
- NEO $689,189,000.00
- Revenue This Year
- HPK N/A
- NEO $10.40
- Revenue Next Year
- HPK N/A
- NEO $10.11
- P/E Ratio
- HPK $8.35
- NEO N/A
- Revenue Growth
- HPK N/A
- NEO 9.70
- 52 Week Low
- HPK $6.60
- NEO $4.72
- 52 Week High
- HPK $15.72
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- HPK 45.89
- NEO 67.10
- Support Level
- HPK $6.81
- NEO $7.56
- Resistance Level
- HPK $7.46
- NEO $8.01
- Average True Range (ATR)
- HPK 0.35
- NEO 0.38
- MACD
- HPK 0.07
- NEO 0.06
- Stochastic Oscillator
- HPK 57.92
- NEO 92.86
About HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.